Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

634
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
634
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

138
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
138
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

144
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
144
Modified-Release Drug Delivery Systems: Stimuli-Activated01:30

Modified-Release Drug Delivery Systems: Stimuli-Activated

153
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
153

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dual Antiplatelet Therapy Duration in Patients at High Bleeding Risk: A Systematic Review and Meta-Analysis.

JAMA cardiology·2026
Same author

Prognostic value of early haemodynamic valve deterioration after TAVI.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2026
Same author

Clinical Impact of Myocardium at Risk in Transcatheter Aortic Valve Implantation.

Circulation. Cardiovascular interventions·2026
Same author

Pharmacodynamic effects of cangrelor in patients with or without STEMI undergoing percutaneous coronary intervention: insights from the POMPEII study.

European heart journal. Acute cardiovascular care·2026
Same author

Ischaemic and bleeding events after complex versus non-complex PCI: a systematic review and meta-analysis.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2026
Same author

Gender, diversity, and inclusion in phenotypic and genetic characterization of acute coronary syndromes: rationale and design of the prospective multicentre GEDI-ACS registry.

European heart journal open·2026
Same journal

At the Edge of the Possible: A New Standard for Cardiovascular Critical Care.

Cardiology clinics·2026
Same journal

End-of-Life Care in the Cardiovascular Intensive Care Unit.

Cardiology clinics·2026
Same journal

Strategies to Reduce Failure to Rescue after Cardiac Surgery.

Cardiology clinics·2026
Same journal

Embracing Enhanced Recovery After Cardiac Surgery Program.

Cardiology clinics·2026
Same journal

Post-Heart Transplantation Intensive Care Unit Recovery: A Phase-Based Approach.

Cardiology clinics·2026
Same journal

A Practical Guide to Intensive Care Unit Management after Left Ventricular Assist Device Implantation.

Cardiology clinics·2026
See all related articles

Related Experiment Video

Updated: Apr 20, 2026

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
08:13

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

5.1K

Peripheral drug-eluting technology.

Anna Franzone1, Eugenio Stabile1, Bruno Trimarco1

  • 1Division of Cardiology, Department of Advanced Biomedical Sciences, University of Napoli "Federico II", Via S. Pansini 5, Napoli 80131, Italy.

Cardiology Clinics
|December 3, 2014
PubMed
Summary
This summary is machine-generated.

Drug-eluting devices offer improved outcomes for peripheral arterial disease compared to traditional methods. This review covers their development, application in femoro-popliteal lesions, and future potential.

Keywords:
Below-the-kneeDrug-coated balloonsDrug-eluting balloonDrug-eluting stentsFemoropoplitealIn-stent restenosisPeripheral artery diseaseRestenosis

More Related Videos

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention
11:01

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention

Published on: September 18, 2015

12.1K
Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents
06:55

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents

Published on: October 26, 2016

9.6K

Related Experiment Videos

Last Updated: Apr 20, 2026

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
08:13

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

5.1K
Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention
11:01

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention

Published on: September 18, 2015

12.1K
Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents
06:55

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents

Published on: October 26, 2016

9.6K

Area of Science:

  • Vascular Surgery
  • Interventional Cardiology
  • Biomaterials Science

Background:

  • Peripheral arterial disease (PAD) treatment traditionally involves angioplasty and bare metal stents.
  • These methods have limitations in long-term patency, particularly in complex femoro-popliteal and below-the-knee lesions.
  • Drug-eluting devices aim to improve outcomes by delivering therapeutic agents locally.

Purpose of the Study:

  • To review the current knowledge and applications of drug-eluting devices in PAD treatment.
  • To evaluate the performance of drug-eluting stents and drug-coated balloons in femoro-popliteal and infra-popliteal arteries.
  • To discuss ongoing research and novel applications of drug-eluting technologies.

Main Methods:

  • Review of existing literature on drug-eluting devices for PAD.
  • Analysis of clinical trial data for drug-eluting stents and drug-coated balloons.
  • Discussion of technical features and development rationale.

Main Results:

  • Drug-eluting devices demonstrate potential benefits over conventional angioplasty and bare metal stents in femoro-popliteal lesions.
  • Evidence suggests improved patency rates and reduced restenosis in treated arterial segments.
  • Data on below-the-knee and infra-popliteal applications are still evolving.

Conclusions:

  • Drug-eluting devices represent a significant advancement in PAD management.
  • Further research is warranted to optimize their use in various vascular beds and patient populations.
  • Novel applications of drug-eluting technologies hold promise for future PAD therapies.